Fusion genes and fusion gene products are widely employed as biomarkers and therapeutic targets in hematopoietic cancers, but their applications have yet to be appreciated in solid tumors. Here, we report the use of SnowShoes-FTD, a powerful new analytic pipeline that can identify fusion transcripts and assess their redundancy and tumor subtype-specific distribution in primary tumors. In a study of primary breast tumors, SnowShoes-FTD was used to analyze paired-end mRNA-Seq data from a panel of estrogen receptor (ER)
Introduction
Widely used as both biomarkers and therapeutic targets in hematopoietic malignancies, genomic rearrangements and resultant fusion gene products have only recently begun to be appreciated in solid tumors (1, 2) . The development of paired-end RNA sequencing technologies (3) combined with effective analytic pipelines that reduce false discovery rates makes it possible to interrogate the transcriptome of tumor cells and identify fusion transcripts with high confidence. A number of laboratories, including our own, have applied this technology to detection of novel fusion transcripts in established breast cancer cell lines (4) (5) (6) . Fusion transcripts have been reported in a small number of primary breast tumors. The de Bellis group discovered a novel fusion transcript from a single primary breast tumor (7) . Edwin Liu's group analyzed 5 breast tumors using a combination of mate-pair genomic (8) and paired-end RNA sequencing (4) . Although no recurrent fusion transcripts were detected in this study, one fusion transcript (RPS6KB!VMPI) was subsequently detected in about 30% of a larger cohort of 70 breast tumors from Asian women. However, the corresponding RPSK6KB!VMPI fusion gene was not detected by Stephens and colleagues (9) , who used paired-end genomic sequencing to survey genomic rearrangements in 15 primary breast tumors, of which 5 were further analyzed for fusion transcripts. Whereas these data unambiguously indicate that primary breast tumors express fusion transcripts, the redundancy of such chimeric RNAs in breast cancer remains an open question; and no studies published to date have undertaken to survey the distribution of fusion transcripts in breast tumor subtypes.
We developed a novel analytic pipeline, SnowShoes-FTD, which facilitates identification of high confidence fusion transcripts from paired-end mRNA-Seq data (6) . This pipeline has now been applied to detection of fusion transcripts in RNA sequence data from a panel of 8 each estrogen receptor alpha (ESR1) positive (ER þ ), HER2-enriched (HER2 þ ), and triple negative (TN) primary breast tumors (24 tumors total). In addition, we analyzed mRNA sequence data from 8 Table S1 ). The quantities of the fusion transcripts were calculated as the number of fusion encompassing reads per million aligned reads. Normal tissue mRNASeq data (50 base paired-end, 73-80 million read pairs per sample) from the Body Map 2.0 project were obtained from ArrayExpress (12) . Paired-end sequence data from nontransformed human mammary epithelial cells (6) were reanalyzed, as described below.
Identification of fusion transcripts
End pairs were aligned to human genome build 36 using Burrows-Wheeler Aligner (13) . The aligned SAM files were sorted according to read IDs using the SAMtools (Sequence Alignment Map tools; ref. 14) . The fusion transcripts were identified with SnowShoes-FTD (6) version 2.0, which has higher sensitivity without increasing false discovery rate, compared with version 1.0. The SnowShoes analytic pipeline incorporates a number of analytic tools into a coherent workflow so as to facilitate data processing.
Fusion encompassing versus fusion spanning reads
Fusion encompassing reads (15) contain 50 nucleotides from each end which map to different fusion partners. Fusion spanning reads include one end that maps within one of the 2 fusion partners and a second end that spans the junction between the 2 different fusion partners. Sentinel fusion transcripts are defined as those detected in a single tumor with 3 or more unique, tiling fusion encompassing read pairs plus 2 or more unique, tiling fusion spanning reads. Moreover, alignment of these reads must allow unambiguous assignment of directionality (5 0 -3 0 ) of the 2 fusion partners. Our initial analysis of fusion transcripts in breast cancer cell lines indicates that sentinel transcripts are predicted with very high accuracy (6) . A select subset of sentinel transcripts from the breast tumors was validated, as shown in Supplementary Figure S1 .
Private versus redundant fusion transcripts
A private fusion transcript is detected in only 1 tumor sample. All private transcripts, by definition, have sentinel properties. Redundant transcripts are detected in 2 or more tumors. A redundant transcript must exhibit sentinel properties in at least 1 tumor.
Tumor-specific fusion transcripts
Fusion transcripts in breast tumors were filtered to remove all candidates that were also detected in either one of the 
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Results and Discussion
We detected 131 sentinel fusion transcripts in 24 tumors (Supplementary Table S2 ). The majority of the fusion transcripts arose from interchromosomal fusions (104 of 131). We had previously identified fusion transcripts that were expressed in multiple isoforms in breast cancer cell lines (6) . Six fusion transcripts were expressed as multiple isoforms in tumors (yellow highlight Supplementary Table S2 .) The majority of the fusion transcripts were "private," expressed in only one tumor sample. However, 45 sentinel transcripts were 
(Continued on the following page) Table S2 .) It will be of interest to determine whether expression of large numbers of fusion transcripts in a subset of HER2 þ tumors has therapeutic implications.
We conclude that fusion transcripts represent a heretofore underappreciated class of genomic features that may have considerable potential as biomarkers or therapeutic targets in breast cancer, and it will be interesting to determine whether the number or characteristics of fusion transcripts correlates with clinical outcome in HER2 þ or other tumor subtypes.
Chromosomal distribution of fusion transcript partners
The chromosomal mapping distribution of the sentinel fusions is clearly nonrandom (Fig. 1A) . A disproportionately large number of fusion transcript partners are located on chromosomes 1, 2, 17, and 19 (Fig. 1B) , whereas relatively few fusion transcript partners are located on chromosomes 4, 9, 13, 15, 20, and 21. It is difficult, because of the relatively small numbers, to make any rigorous conclusions with respect to tumor subtype-specific distribution of fusion transcripts. However, chromosome 19 seems to be a "hot spot" for TN tumors. Circos plots of ER þ -specific and TN-specific redundant fusion gene partners (Fig. 1A) indicate that there is a subtype-specific fusion transcript geography, suggesting a functional link between breast tumor subtype and formation of fusion transcripts. The observation that HER2 þ tumors, as a group, express significantly fewer fusion transcripts is consistent with this hypothesis. A number of distinct clusters emerged when the fusion partner genes were mapped to genomic loci (Fig. 2) . Two major clusters were observed on chromosome 17, mapping to 17q21-q23, and 17q25. Both of these regions are well known to undergo copy number variation in breast cancer. All of the (green arrow in Fig. 2 ), a small cluster of genes at 1q21.2-q21.3 was restricted to HER2 þ tumors (blue arrow in Fig. 2) , and genes that clustered at 8q24.3, 12q13.13, and 17q25.1-q25.3 were restricted to TN tumors (red arrows in Fig. 2 ). Limited data from genomic analysis of both breast cancer cell lines (5) and tumors (4, 9) indicate that genomic rearrangement is the primary mechanism whereby most fusion transcripts are generated. Furthermore, review of the array comparative genomic hybridization (aCGH) data on breast cancer reveals that many of the fusion partners that we have identified map to regions that are known to undergo copy number gain or loss in breast tumors. This correlation is most obvious when one considers chromosome 17, which contains 33 genes that contribute to fusion transcripts. Among these genes, 6 map to a cluster at 17q12, 5 to 17q21, and 6 to 17q25. All 3 of these loci are known to undergo copy number variation in breast cancer (9, (16) (17) (18) . The distribution of fusion partners on chromosome 19 is even more striking. All of the genes map to either 19p12-p13 or 19q13. Both aCGH and genome wide association data indicate that these 2 regions are important in breast cancer, particularly the TN subtype (19, 20) . Based on these considerations, we posit that most of the fusion transcripts arise due to chromosomal rearrangements and therefore mark areas of local chromosomal instability.
Structure and potential functional significance of predicted fusion transcript products SnowShoes_FTD assembles the predicted nucleotide sequences of the candidate fusion transcripts and translates that sequence into the predicted amino acid sequences of the putative fusion proteins (Supplementary Table S3 ). We and others have shown that fusion transcripts in breast cancer cell lines fall into several broad categories based on the location within the transcription unit wherein the fusion occurs (5, 6) . A small number of fusions occur in 5 0 untranslated region (UTR) regions (Table 2) , placing the coding sequence of the 3 0 fusion partner under the control of the promoter from the 5 0 fusion partner. We have reported that a "promoter swap" event of this sort is associated with ERBB2 overexpression in a breast cancer cell line derived from a HER2 þ tumor (6). The most common class of fusion transcripts in cell lines occur within 3 0 UTR). A similar distribution prevailed in primary breast tumors (Table 2) . Such fusions result in the generation of full-length coding sequences of the 5 0 fusion partner, but alter the 3 0 UTR sequence of such transcripts, with potential effects on stability and/or translational efficiency of the fusion transcript (21) .
The second broad class of chimeric transcripts involves fusion within the coding regions. Some of these transcripts contain precise exon/exon junctions (column H Supplementary Table S2 ) and are assumed to be processed. However, our data do not discriminate between tumor-specific trans-splicing events and processing of a primary transcript that arises due to genomic rearrangement. The fusion junctions of many chimeric transcripts do not correspond to known exon/exon boundaries. These may arise due to trans-splicing at cryptic sites or, more likely, represent novel exonic sequences derived from transcription of rearranged genes.
Coding sequence fusions fall into 2 classes. We identified 25 fusion transcripts that are predicted to give rise to chimeric proteins, many of which contain functional domains from both fusion partners and might therefore be expected to have novel properties [coding inframe fusion (CIF) in Table 2 ]. The deduced sequence and functional domains of all predicted fusion products is given in Supplementary Table S4 . By way of example, the TFG!GPR128 fusion transcript is predicted to encode a novel 848 amino acid protein in which the PB1 protein-protein interaction domain of TFG (also known as the TRKT3 oncogene) is fused to the 7 transmembrane spanning domain of GPR128, with loss of the serine/threonine-rich N-terminal domain that is characteristic of this subclass of G-protein-coupled receptors. The potential regulatory effects of such a chimeric protein might be considerable, and the fact that these hypothetical signaling changes might devolve from a G-protein-coupled receptor makes this a potentially druggable target.
About half of the coding to coding fusions were predicted to result in frame shifts and carboxy-terminal truncation of the 5 0 fusion partner (CTT in Table 2 ). To the extent to which such transcripts escape nonsense-mediated degradation mechanisms, they would be predicted to encode N-terminal polypeptides that are deleted of C-terminal functional domains. For example, the ADCY9!C16orf5 fusion transcript is predicted to encode a polypeptide of 585 amino acids that includes the N-terminal nucleotide binding domain of adenylylate cyclase 9, but is deleted of the C-terminal nucleotide cyclase domain and therefore unlikely to have catalytic activity. However, the N-terminal fragment contains the intact dimerization domain of ADCY9 and might therefore function as a dominant-negative inhibitor.
The functional significance of fusion transcripts in breast cancer is an area of very active investigation. The objective is to identify tumor specific, druggable fusion transcripts that are required for establishment and maintenance of the transformed phenotype (e.g., BCR-ABL1). The existence of driver fusion transcripts of this sort remains to be established in breast cancer. However, the potential significance of fusion transcripts as biomarkers does not depend upon such entities serving as driver mutations; and we are confident that a more comprehensive analysis of fusion transcripts in breast cancer will provide a set of novel biomarkers that will be useful for stratification of tumor subtypes, prediction, and prognosis. Ultimately, we anticipate that some of these fusion transcripts will emerge as therapeutic targets for treatment of the more challenging breast tumor subtypes, including HER2 þ tumors with both de novo and acquired resistance to targeted therapy, hormone-resistant ER þ tumors, and TN tumors.
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